Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(8%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
17%
Ph phase_2
2
17%
Ph phase_3
1
8%
Ph phase_4
3
25%
Ph not_applicable
4
33%

Phase Distribution

2

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
1(8.3%)
Phase 4Post-market surveillance
3(25.0%)
N/ANon-phased studies
4(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(6)
Terminated(1)
Other(3)

Detailed Status

Completed6
unknown3
Active, not recruiting1
Enrolling by invitation1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 22 (16.7%)
Phase 31 (8.3%)
Phase 43 (25.0%)
N/A4 (33.3%)

Trials by Status

completed650%
active_not_recruiting18%
enrolling_by_invitation18%
unknown325%
withdrawn18%

Recent Activity

Clinical Trials (12)

Drug Details

Intervention Type
OTHER
Total Trials
12